The economic burden of cancer in the UK: a study of survivors treated with curative intent. by Marti, J et al.
1 
 
The economic burden of cancer in the UK: a study of survivors treated with 
curative intent 
 
 
*Marti Ja 
Hall PSa,b  
Hamilton Pa 
Hulme CTa 
Jones Hc 
Velikova Gc  
Ashley Ld 
Wright Pc 
   
a. Academic Unit of Health Economics, University of Leeds, Leeds, UK. 
b. Edinburgh Cancer Research Centre, University of Edinburgh, UK. 
c. Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, UK. 
d. Faculty of Health and Social Sciences, Leeds Beckett University, Leeds, UK.  
 
 
*Corresponding:j.e.marti@leeds.ac.uk 
 
 
The authors declare that they have no conflict of interest. 
 
 
Acknowledgements 
The electronic Patient-reported Outcomes from Cancer Survivors (ePOCS) study 
was funded by Macmillan Cancer Support. We would like to thank the Corporate 
Finance Department of the National Health Service Leeds Teaching Hospitals Trust 
(LTHT) including Wendy Allott and Joe Selfridge who provided data from the LTHT 
Patient Level Information and Costing System. 
 
  
2 
 
Abstract 
 
Objective: To describe the economic burden of UK cancer survivorship for breast, 
colorectal and prostate cancer patients treated with curative intent, one year post-
diagnosis.  
 
Methods: Patient-level data were collected over a three-month period 12-15 months 
post-diagnosis to estimate the monthly societal costs incurred by cancer survivors. 
Self-reported resource utilisation data were obtained via the electronic Patient-
reported Outcomes from Cancer Survivors (ePOCS) system and included 
community-based health and social care, medications, travel costs and informal 
care. Hospital costs were retrieved through data linkage. Multivariate regression 
analysis was used to examine cost predictors. 
 
Results: Overall 298 patients were included in the analysis, including 136 breast 
cancer, 83 colorectal cancer and 79 prostate cancer patients. The average monthly 
societal cost was $US409 (95%CI:$US316-$US502) [mean:£260, 95%CI:£198-
£322] and was incurred by 92% of patients. This was divided into costs to the 
National Health Service (NHS) (mean:$US279, 95%CI:$US207-$US351) 
[mean:£177; 95%CI:£131-£224], patients’ out-of-pocket (OOP) expenses 
(mean:$US40, 95%CI:$US15-$US65) [mean:£25; 95%CI:£9-£42] and the cost of 
informal care (mean:$US110, 95%CI:$US57-$US162) [mean:£70; 95%CI:£38-£102]. 
The distribution of costs was skewed with a small number of patients incurring very 
high costs. Multivariate analyses showed higher societal costs for breast cancer 
patients. Significant predictors of OOP costs included age and socioeconomic 
deprivation.  
 
Conclusions: This study found the economic burden of cancer survivorship is 
unevenly distributed in the population and that cancer survivors may still incur 
substantial costs over 1 year post-diagnosis. In addition, this study illustrates the 
feasibility of using an innovative online data collection platform to collect patient-
reported resource utilisation information. 
 
Keywords: oncology, cancer survivorship, costs, out-of-pocket expenses, informal 
care, economics. 
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Introduction 
Cancer is becoming increasingly survivable thanks to advances in treatment and 
early detection. Better prognosis and a growing population in high-incidence age 
groups have led to a rising number of cancer survivors. There are approximately two 
million cancer survivors in the UK and this figure is expected to double by 2030 [1,2], 
which warrants a better understanding of the economic consequences of cancer 
survivorship.  
It has been shown that 80% of UK cancer patients are more than one year 
away from both diagnosis and death and had not used any cancer-related acute 
health care in a given year [3]. While a substantial portion of costs is incurred during 
the first year following diagnosis [4-6], cancer may impose a significant economic 
burden on patients and the health system in the longer-term. Survivors may require 
continuing inpatient and outpatient care and support from relatives. While in the UK, 
the National Health Service (NHS) may cover costs such as community-based care 
and prescribed medications, other costs, such as travel to appointments or child care 
are mostly incurred by patients. In addition, informal care is time-consuming and has 
often been overlooked in economic evaluations in cancer [7,8]. 
Cost-of-illness studies in cancer vary widely in methodology, data type and 
level of aggregation making cross-study comparisons challenging. Most existing 
studies have focused on direct medical costs during the initial period of care and 
have been conducted in the United States or in other countries with disparate health 
systems with varying levels of direct financial participation from patients [9-19]. As 
the UK health system is predominantly publicly funded and mostly free at the point of 
use, results from most of these studies are not generalizable to the UK. Notable 
exceptions are studies conducted in Canada whose health system is also mainly 
public. Overall, there is a dearth of UK studies on the cost of cancer and, in 
particular, on the cost of cancer survivorship and related informal care. An exception 
is Macmillan’s recent unpublished prospective study of over 1,600 cancer patients 
which found 83% incurred an average monthly economic loss following diagnosis of 
$US900 (£570), with lost earnings and out-of-pocket (OOP) expenses accounting for 
the largest share of the burden [20]. While informative, this study had a low response 
rate (37%) and a heterogeneous sample that included both recently diagnosed 
patients and long-term survivors with multiple cancer types. The full economic impact 
of cancer survivorship on the UK NHS and on society as a whole is therefore not 
fully understood.  
Our study aimed to fill this gap by: (1) describing the economic burden of 
cancer survivorship in the UK from a societal perspective for breast, colorectal and 
prostate cancer patients (three of the four most common UK cancers and the largest 
survivor groups [2]) treated with curative intent and (2) examining independent cost 
predictors. 
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Materials and methods 
Framework for analysis 
We used a standard cost-of-illness framework [21] such that we estimated direct 
medical costs and informal care time costs, and labelled the sum of all cost 
categories as societal costs. Direct medical costs are the actual expenditures related 
to health care utilisation for cancer treatment, continuing care and rehabilitation that 
are borne either by the NHS or paid directly OOP by the patient. The former include 
hospital costs, the use of community-based health and social care, and the use of 
medications reimbursed by the NHS. The latter include medications paid OOP, travel 
costs to and from appointments and extra expenses (e.g. child care). Informal care 
time costs were evaluated with the human capital approach [22] by assigning the 
relevant market value to the time spent by family and friends to provide care. In this 
study, we were not able to quantify patients’ productivity losses (or indirect costs). 
See Figure 1 for an overview of the cost categories.   
Data and sample 
Multiple data sources were linked to obtain relevant patient-level clinical and financial 
information for a three-month period 12-15 months post-diagnosis. Non-hospital 
resource use data were collected as part of a feasibility study to test a novel 
electronic system for collecting patient-reported outcomes online; the electronic 
Patient-reported Outcomes from Cancer Survivors (ePOCS) system. Comprehensive 
accounts of the design and development of the ePOCS system [23], the protocol [24] 
and results [25] of the feasibility study have been published open-access. The 
ePOCS study received NHS ethical approval (ref.10/H1306/65). In the study, adult 
patients were recruited from Leeds Teaching Hospitals NHS Trust (LTHT) and 
Calderdale & Huddersfield NHS Foundation Trust (CHFT) and were eligible to 
participate if diagnosed with potentially curable breast, colorectal or prostate cancer 
within the last 6 months, and if English literate. Recruitment was undertaken by NHS 
clinicians and research nurses. Efforts were made to approach all consecutive 
eligible patients. Patients in the feasibility study completed quality-of-life 
questionnaires using the ePOCS system at three time-points; within 6 months of 
diagnosis (T1), and at 9 (T2) and 15 (T3) months post-diagnosis. At T3 patients 
completed a financial cost of cancer (FCC) questionnaire about the resources they 
had used as a result of cancer and its treatment in the previous three months (see 
supplemental appendix). The ePOCS system allowed patients’ questionnaire 
responses to be linked with their sociodemographic and clinical cancer registry data. 
We used information on gender, age at diagnosis, diagnosis (breast, colorectal or 
prostate cancer), treatment (i.e. chemotherapy, surgery, hormone therapy, 
radiotherapy) and level of socioeconomic deprivation measured via the index of 
multiple deprivation (IMD) calculated from patients’ postcodes [26]. Hospital costs 
were obtained through linkage with the pilot database of the National Patient-Level 
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Information and Costing System (PLICS) using patients’ NHS numbers. PLICS 
provides new opportunities for the calculation of the complete hospital-based cost of 
care, and offers an improvement over current methods which rely on coded Human 
Resource Groups (HRGs) and assigned national standard tariffs.  
Costing analysis 
We used a micro-costing approach where we first collected information on resource 
utilisation at the individual level and then, where appropriate, applied standardised 
unit costs to obtain patient-level costs [22].  
In the FCC questionnaire (see supplemental appendix), patients were asked 
to report the number of contacts over the previous three months with various 
different health professionals (e.g. GP, practice nurse), as well as where each 
contact took place (e.g. on the phone, at the hospital, etc.). The unit cost of each 
contact type was obtained from the Personal Social Services Research Unit of 
Health and Social Care [27]. Patients were asked to provide information on their 
medications (e.g. name, dose) and whether they paid for their prescriptions. The 
price of each medication was obtained from the British National Formulary [28]. The 
cost of medication to the NHS was calculated depending on whether patients paid 
for their prescriptions.  If a patient paid for their prescription this was taken at a cost 
of $US12.10 (£7.65) per item and this charge was taken off the total cost of that 
medication accrued over the three-month period. Patient OOP medication costs 
included the cost of over the counter medications and the cost of prescriptions if 
patients paid for them. The cost of travel to appointments was based on the distance 
travelled by car by the patient to and from appointments at a price of $US0.35 
(£0.22) per mile [29] and on the total cost of using public transport and taxis. Extra 
costs included all patient-reported OOP expenses incurred by them or their carers as 
a result of cancer over the three-month period, such as paying for additional heating, 
childcare or incontinence pads. Patients were then asked to report the average 
number of hours per week family and friends had given them practical help as a 
consequence of cancer over the previous three months. This number was multiplied 
by the number of weeks (12) and the median hourly wage of home care workers 
($US11(£7)) to obtain a conservative estimate of the economic value of informal care 
[27]. Because the patient FCC questionnaires were completed over a one-year time 
period (August 2011-October 2012), costs were not discounted. 
Costs of hospital care were extracted from PLICS for each of the patients 
within the study over the time period of interest. PLICS records costs at the patient 
level for hospital-based accident and emergency department visits, outpatient 
attendances and inpatient stays. Individual care episodes are coded using the 
national HRG version 4 codes. HRG costing uses a mixture of: (a) top-down costing 
– where cost pools are allocated to HRGs using the total cost of that cost pool 
weighted for each HRG based upon the best available data and, (b) bottom-up 
costing – which builds up the costs of an HRG from known local expenditure HRGs 
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[30]. The costs contained within the PLICS database are derived entirely by bottom-
up costing. 
Statistical analyses 
We used descriptive statistics to summarise societal costs, including NHS costs, 
patients OOP expenses and the costs of informal care. To facilitate interpretation 
and ensure comparability with earlier studies, we present monthly costs in each cost 
category. We examined associations between monthly costs and age (>70), gender, 
IMD (least deprived category), cancer site, treatment type, and hospital using two-
part models to account for the high proportion of patients that incurred zero costs 
and for the skewness of the positive cost distribution. The first part of the model 
examines the probability of experiencing any cost using logistic regression, and the 
second part models the level of cost among those who have positive costs using 
generalized linear model with gamma family and log link [31,32]. The models were 
estimated for all cancer sites combined.  
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Results 
Patients’ characteristics 
Of 1,152 eligible patients invited to join the ePOCS feasibility study, 636 (55.2%) 
consented to participate. Participants were significantly younger and more affluent 
than declining patients, although there were no differences by gender, diagnosis or 
time post-diagnosis. The majority of patients who offered a reason for non-
participation cited technology-related issues (e.g. no computer/Internet access, do 
not like computers) [25]. We identified patients in the ePOCS study (N=636) who had 
not experienced a recurrence of their cancer and who had completed the FCC 
questionnaire 15 months post-diagnosis (n=397). As PLICS data were not available 
for CHFT patients, these patients were excluded from the analysis (n=83). Finally, 
we excluded 16 patients who had missing information on most items in the FCC 
questionnaire. Overall, 298 patients were included in the analysis. Table 1 provides 
information on patients’ sociodemographic and clinical characteristics. Compared to 
the ‘baseline’ sample (N=636), patients who completed the FCC questionnaire were 
younger, more likely to have prostate cancer, less likely to have colorectal cancer 
and lived in less deprived areas.  
Costs 
Costs in each category are presented in Table 2. The mean monthly societal cost 
was $US409 (95%CI:$US316-$US502) [mean:£260, 95%CI:£198-£322]. This 
comprised costs to the NHS (mean:$US279, 95%CI:$US207-$US351)[mean:£177; 
95%CI:£131-£224], patient OOP expenses (mean:$US40, 95%CI:$US15-$US65) 
[mean:£25; 95%CI:£9-£42] and informal care (mean:$US110, 95%CI:$US57-
$US162) [mean:£70; 95%CI:£38-£102]. Hospital costs and informal care costs 
accounted for 47% and 27% of total societal costs respectively. A large number of 
patients incurred little or no societal cost although a small proportion had very high 
costs (see supplemental appendix). The proportion of patients incurring any cost 
differed by cost category, with some relatively frequently incurred (68%) but lower 
costs (e.g. travel costs) and others less frequently observed (19%) but higher costs 
(e.g. cost of informal care).  
 Costs in the three main categories were estimated by cancer site (Table 3). 
Results show that breast cancer patients incurred significantly higher monthly costs, 
mainly due to higher NHS costs. Costs for prostate cancer patients were lower in all 
cost categories. Seven patients incurred monthly costs above $US3,160 (£2,000). 
The main cost driver was hospital costs for five of these patients and informal care 
for two patients who required extensive support from family and/or friends (>90 hours 
per week). Although the mean OOP cost is relatively low in this sample at $US40 
(£25), 11 (3.7%) patients incurred more than $US158 (£100) a month in OOP 
expenses over the period. The majority (54.5%) of these patients had breast cancer 
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and main cost drivers were non-prescription medicines (e.g. Glucosamine, Vitamin 
E), and extra costs (e.g. child care and additional heating). 
Results from the two-part models showed that prostate cancer patients were less 
likely to incur any societal cost than breast cancer patients and that, among those 
with costs, observed costs were lower. Patients who underwent radiotherapy were 
more likely to incur any societal and NHS cost, but they incurred lower costs on 
average. Models for NHS and OOP costs indicated that both colorectal and prostate 
cancer patients were less likely than breast cancer patients to incur any cancer-
related costs. The second part of the OOP model showed that patients in the older 
age group incurred lower OOP costs, and that patients who live in the least deprived 
areas (i.e. lower quintile of socioeconomic deprivation) had higher OOP costs (see 
supplemental appendix).  
 
Discussion 
This paper analysed multiple data sources to estimate the economic burden of 
cancer survivorship at the patient level in the UK. Our estimates will inform economic 
evaluations of alternative technologies and practices in supportive cancer care. We 
found an average monthly societal cost of $US409 (£260) among this sample of 
breast, colorectal and prostate cancer patients one-year post-diagnosis. The recent 
unpublished Macmillan study found an average monthly cost of $US900 (£570), but 
their survey included both recently diagnosed patients and survivors, and included 
productivity losses in the analyses [20]. Other estimates yielded higher monthly 
costs, but were focused on direct costs in the intensive phase of care ($US526 
(£333)/month) [33] or on more severely ill patients ($US1,513 (£958)/month) [34]. 
Our analysis showed that societal costs are mainly attributable to NHS and informal 
care costs, rather than patients’ OOP expenses. Importantly, a majority of patients 
experienced little or no cost, but a small number of patients incurred very high costs, 
as previously found [20]. When comparing costs across cancer sites, we found that 
breast cancer patients had higher costs, mainly due to high NHS costs, which was 
confirmed in the multivariate analysis. These results contrast with previous findings 
from the US and Canada where studies found higher health system costs for 
colorectal cancer patients compared to breast and prostate cancer patients [4-6,35]. 
It is worth noting these studies relied mostly on population-based samples whereas 
we analysed a small sample, which may not be representative of the UK population 
of cancer survivors. In addition, three of these studies focused on the initial treatment 
period, up to 12 months post-diagnosis [4-6], and the other study included patients 
65 years and older only [35], making direct comparisons difficult. The time frame of 
interest is important as most patients in all three groups are likely to have completed 
expensive primary treatment by twelve months post diagnosis. In addition, these 
previous studies include older data. In recent years new and relatively costly drugs 
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have been introduced for some groups of breast cancer patients following primary 
NHS treatment (e.g. Herceptin).  
Overall, even in this sample of relatively healthy patients, the societal costs 
are not negligible and substantial support from family and friends was required. Our 
findings echo those of recent studies that highlight the importance of time cost for 
informal care in cancer survivorship [7,8]. In our sample, the main drivers of societal 
costs were costly hospital stays and extensive recourse to informal care. A possible 
explanation for this may be the presence of multiple long-term conditions in this 
patient group. While we do not have information on comorbidities, recent research 
has shown that more than half of cancer patients report having at least one other 
long-term condition [36]. Multivariate analyses showed that prostate cancer patients 
had consistently lower societal costs than breast cancer patients. When OOP 
expenses were analysed, we found that patients living in more deprived areas and 
who were older were less likely to incur high OOP expenses. While difficult to explain 
with the data at hand, the lower OOP costs among less affluent patients may be due 
to shorter distances travelled for inpatient treatments in this group [37]. An 
alternative explanation indicated by several observations in our sample is the more 
frequent use of non-prescription medicines among higher income breast cancer 
patients [38]. Regarding age, while older people may have accumulated assets over 
a lifetime, they are likely to have relatively low disposable income. In addition, some 
services such as travel on public transport that are costly for younger patients may 
be free at older age.  
We were able to collect detailed information on NHS costs, OOP expenses 
and support from family and friends. The novelty of our approach lies in the use of 
new data collection platforms. The estimation of detailed hospital costs was 
performed using a new patient-level costing system and the patient-reported 
information on resource use was collected via the innovative web-based ePOCS 
system [23-25]. However, this study has several limitations that should be noted. 
First, we estimated societal costs based on data collected over a three-month period 
and hence have described only a “snapshot” of the burden of cancer survivorship. 
However, the focus on a short and recent time period will have likely enhanced recall 
accuracy among patients. Recall time frame and data collection platform are 
important determinants of recall accuracy in self-reported use of health care services 
[39]. A three-month period offers a good trade-off between accuracy and the risk of 
fluctuation of costs. Overall, our figures are likely to reflect a conservative estimate of 
the economic burden of cancer as it has been shown that patients often underreport 
resource utilisation [39]. Second, while respondents were asked to report specifically 
“resources used as a result of cancer and cancer treatment”, we cannot rule out that 
our estimates reflect some non-cancer-related costs. Third, the ePOCS feasibility 
study was restricted to English-literate patients and, as is often the case in research 
studies [40], those who joined were younger and more affluent than non- 
participants; this may limit the generalizability of our findings. Fourth, we were unable 
to recover detailed information on patients’ productivity losses. Recent estimates 
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have shown lost earnings account for more than 25% of the economic cost of cancer 
survivorship [20]. More data about the number of cancer-related working days lost 
would have been required to produce a comparable estimate. Another limitation is 
the lack of staging information included in the analysis. It is difficult to make 
comparisons between diagnostic groups using the different types of stage and the 
sample sizes were too small to perform the analyses by cancer type. In addition, 
staging information was missing for more than 10% of patients.  
Given the increasing number of patients living with and beyond cancer, more 
research is needed to obtain a comprehensive understanding of the economic 
burden of cancer survivorship. In particular, as family and friends seem to provide 
crucial support for cancer survivors, studies which provide a more detailed account 
of the economic burden of informal care in cancer survivorship are needed [7,8]. As 
health care utilisation information is costly to routinely collect, especially in a chronic 
disease setting, a web-based system such as ePOCS could facilitate collection of 
the information required to undertake comprehensive economic analyses. 
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Table 1: Patient characteristics 
 Full sample 
(n=298) 
Breast 
(n=136) 
Colorectal 
(n=83) 
Prostate 
(n=79) 
Gender (%)     
Male 134(45.0) 0(0) 55(66.3) 79(100) 
Female 164(55.0) 136(100) 28(33.7) 0(0) 
Age at diagnosis (%)     
0-50 54(18.1) 43(31.6) 10(12.0) 1(1.3) 
51-60 77(25.8) 41(30.1) 21(25.3) 15(19.0) 
61-70 122(40.9) 40(29.4) 32(38.6) 50(63.3) 
70+ 45(15.1) 12(8.8) 20(24.1) 13(16.5) 
Employment status at interview (%)     
Employed (full-time) 76(25.5) 44(32.4) 14(16.9) 18(22.8) 
Employed (part-time) 45(15.1) 34(25.0) 5(6.0) 6(7.6) 
Unemployed  9(3.0) 1(0.7) 6(7.2) 2(2.5) 
Retired 142(47.7) 41(30.1) 51(61.4) 50(63.3) 
Other 20(6.7) 13(9.6) 5(6.0) 2(2.5) 
Missing 6(2.0) 3(2.2) 2(2.4) 1(1.3) 
Treatment (%)     
Chemotherapy 130(43.6) 87(64.0) 43(51.8) 0(0) 
Surgery 196(65.8) 119(87.5) 60(72.3) 17(21.5) 
Hormone therapy 56(18.8) 48(35.3) 0(0) 8(10.1) 
Radiotherapy 113(37.9) 61(44.9) 12(14.5) 40(50.6) 
No treatment  31(10.4) 1(0.7) 7(8.4) 23(29.1) 
Socioeconomic status (%)     
1 (most deprived IMD 
a
 quintile) 44(14.8) 19(14.0) 18(21.7) 7(8.9) 
2 50(16.8) 22(16.2) 16(19.3) 12(15.2) 
3 48(16.1) 21(15.4) 11(13.3) 16(20.3) 
4 79(26.5) 37(27.2) 19(22.9) 23(29.1) 
5 (least deprived IMD
 a
 quintile) 77(25.8) 37(27.2) 19(22.9) 21(26.6) 
Breast cancer stage (%)     
Stage 1  69(50.7)   
Stage 2  42(30.9)   
Stage 3  10(7.4)   
Stage 4  1(0.7)   
Missing  14(10.2)   
Colorectal cancer stage (%)     
Duke’s A   17(20.5)  
Duke’s B   23(27.7)  
Duke’s C   26(31.3)  
Duke’s D   2(2.4)  
Missing   15(18.1)  
Prostate cancer Gleason score (%)     
6    24(30.4) 
7    40(50.6) 
8    1(1.3) 
9    6(7.6) 
Missing    8(10.1) 
a
Index of Multiple Deprivation 
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Table 2:  Monthly costs over the 12-15 months post-diagnosis period (2012 $US) 
 % with 
cost 
Mean  Mean (without 
outliers)
d
 
95%CI Min (if cost>0) Max  
Costs to the NHS
a
       
Hospital costs 34.2 $194.2(£122.9)  $169.2(£107.1) $127.5-$206.7(£80.7-£165.0) $36.7(£23.2) $4045.3(£2560.3) 
Community-based care 58.4 $65.9(£41.7) $57.4(£36.3) $48.7-$83.3(£30.8-£52.7) $11.5(£7.3) $1433.5(£907.3) 
Cost of medications to 
the NHS 
48.7 $19.3(£12.2) $15.8(£10.0) $12.3-$26.2(£7.8-£16.6) $0.09(£0.06)  $541.6(£342.8) 
Patients’ out-of-
pocket costs 
      
Cost of medications to 
the patient 
9.1 $11.9(£7.5) $5.4(£3.4) $-1.9-$25.6(£-1.2-£16.2) $0.2(£0.1)  $1473.8(£932.8) 
Travel costs 68.1 $7.1(£4.5) $6.0(£3.8) $4.9-$9.2(£3.1-£5.8) $0.3(£0.2) $167.5(£106.0) 
Extra costs 7.0 $21.0(£13.3) $15.3(£9.7) $-1.3-$43.6(-£0.8-£27.6) $5.2(£3.3) $3028.4(£1916.7) 
Costs of informal care       
Value of carers’ time
b
 18.9 $69.4(£109.7) $80.3(£50.8) $58.3-$161.0(£36.9-£101.9) $44.2(£28) $4645.2(£2940.0) 
Total costs       
NHS costs 82.9 $279.3(£176.8)  $254.7(£161.2) $207.3-$351.4(£131.2-£222.4)  $0.3(£0.2) $4068.3(£2574.9) 
Patient OOP
c
 costs 69.5 $39.8(£25.2) $26.9(£17.0) $14.5-$65.3(£9.2-£41.3) $0.3(£0.2) $3028.4(£1916.7) 
Informal care costs
b
 18.7 $109.7(£69.4) $80.3(£50.8) $57.4-$162.1(£36.3-£102.6) $44.2(£28) $4645.2(£2940.0) 
Total societal costs
b
 91.7 $408.9(£258.8) $372.3(£235.6) $315.5-$502.4(£199.7-£318.0) $0.3(£0.2) $5711.9(£3615.1) 
a
National Health Service; 
b
Based on 288 observations with available carer time information; 
c
Out-of-pocket; 
d
Outliers are defined as patients with costs equal to or above the 99
th
 percentile 
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Table 3: Mean (95%CI) monthly costs across cancer type (2012 $US) 
 Full sample (n=298) Breast (n=136)   Colorectal (n=83)  Prostate (n=79) 
NHS costs $279.3($207.3-$351.4)  $394.2($261.5-$526.9) $218.4($118.5-$318.4) $145.5($77.9-$213.1) 
 £176.8(£130.3-£223.3) £249.5(£165.5-£333.5) £138.2(£75.0-£201.5) £92.1(£49.3-£134.9) 
Patient OOP
a
 costs $39.8($14.5-$65.3) $49.0($12.2-$86.0) $52.0($-22.9-$126.9) $11.4($3.6-$19.0) 
 £25.2(£8.9-£41.6) £31.0(£7.7-£54.4) £32.9(-£14.5-£80.3) £7.2(£2.3-£12.0) 
Informal care costs
b
 $109.7($57.4-$162.1) $111.9($37.0-$186.8) $187.5($64.3-$310.8) $25.9($-8.7-$60.5) 
 £69.4(£37.0-£101.9) £70.8(£23.4-£118.2) £118.7(£40.7-£196.7) £16.4(-£5.5-£38.3) 
Total societal
 b
 $408.9($315.5-$502.4) $528.7($366.4-690.8) $426.0($251.2-$600.7) $186.3($108.9-$263.9) 
 £258.8(£197.4-£320.2) £334.6(£231.9-£437.2) £269.6(£159.0-£380.2) £117.9(£68.9-£167.0) 
a
Out-of-pocket; 
b
Based on 288 observations with available carer time information 
  
17 
 
 
Figure 1: Overview of the cost categories 
 
 
 
 
